Linked Life Data

2047664

Source:http://linkedlifedata.com/resource/pubmed/id/2047664

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1991-7-17
pubmed:abstractText
Only indirect evidence has been cited to document that lipopolysaccharide-mediated virulence at the bacterial level and serum antibodies to the O-specific side chain of the lipopolysaccharide molecule may prevent shigellosis. Our proposed use of the B subunit of Shiga toxin as a carrier protein is based upon evidence (even more indirect) that serum antitoxin may reduce the severity of dysentery and diarrhea. Because animal models of disease may provide information inapplicable to the prediction of vaccine-induced protective immunity, we suggest that clinical trials in the population at risk should be started after successful completion of the safety and immunogenicity phases of vaccine development in laboratory animals and in the target population. Clinical studies of shigella vaccines are difficult because of the many causes of dysentery in a population with a high rate of intestinal disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0162-0886
pubmed:author
pubmed:issnType
Print
pubmed:volume
13 Suppl 4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S362-5
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:articleTitle
O-specific side-chain toxin-protein conjugates as parenteral vaccines for the prevention of shigellosis and related diseases.
pubmed:affiliation
National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
pubmed:publicationType
Journal Article, Review